This Article Full Text Full Text (PDF) All Versions of this Article: 37/8/2100    most recent 01.STR.0000231388.72646.05v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ginsberg, M. D. Articles by Tamariz, D. Search for Related Content PubMed PubMed Citation Articles by Ginsberg, M. D. Articles by Tamariz, D. Related Collections Neuroprotectors Acute Cerebral Infarction

(Stroke. 2006;37:2100.)
© 2006 American Heart Association, Inc.

Original Contributions

The ALIAS Pilot Trial

A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke—I: Physiological Responses and Safety Results

Myron D. Ginsberg, MD; Michael D. Hill, MD, MSc; Yuko Y. Palesch, PhD; Karla J. Ryckborst, BA, RN Diego Tamariz, MD

From the Department of Neurology, University of Miami Miller School of Medicine, Miami, Fla (M.D.G., D.T.); the Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Alberta, Canada (M.D.H., K.J.R.); and the Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, SC (Y.Y.P.).

Correspondence to Myron D. Ginsberg, MD, Department of Neurology (D4-5), University of Miami Miller School of Medicine, PO Box 016960, Miami, FL 33101. E-mail mdginsberg{at}stroke.med.miami.edu

Background and Purpose— In preclinical stroke models, high-dose human albumin confers robust neuroprotection. We investigated the safety and tolerability of this therapy in patients with acute ischemic stroke.

Methods— The ALIAS (Albumin in Acute Stroke) Pilot Clinical Trial used a multiple-tier, open-label, dose-escalation design. Subjects with acute ischemic stroke (NIH Stroke Scale [NIHSS] of 6 or above) received a 2-hour infusion of 25% human albumin (ALB) beginning within 16 hours of stroke onset. Six successive ALB dose tiers were assessed ranging from 0.34 to 2.05 g/kg. Neurologic and cardiac function was sequentially monitored. At 3 months, the NIHSS, modified Rankin Scale, and Barthel Index were measured.

Results— Eighty-two subjects (mean age, 65 years) received ALB at 7.8±3.4 hours after stroke onset (mean±standard deviation). Forty-two patients also received standard-of-care intravenous tissue plasminogen activator (tPA). Vital signs were unaltered by ALB treatment. Dose-related increases in plasma albumin and mild hemodilution were maximal at 4 to 12 hours. Age-related plasma brain natriuretic peptide levels increased at 24 hours after ALB but did not predict cardiac adverse events. The sole ALB-related adverse event was mild or moderate pulmonary edema in 13.4% of subjects, which was readily managed with diuretics. In the tPA-treated subgroup, symptomatic intracranial hemorrhage occurred in only one of 42 subjects.

Conclusions— Twenty-five percent human albumin in doses ranging up to 2.05 g/kg was tolerated by patients with acute ischemic stroke without major dose-limiting complications. tPA therapy did not affect the safety profile of ALB. The companion article presents neurologic outcome data and efficacy analysis in these subjects.

Key Words: ischemia • neuroprotection • outcome • stroke • thrombolysis

This article has been cited by other articles:

				H.-P. Park, A. Nimmagadda, R. A. DeFazio, R. Busto, R. Prado, and M. D. Ginsberg Albumin Therapy Augments the Effect of Thrombolysis on Local Vascular Dynamics in a Rat Model of Arteriolar Thrombosis: A Two-Photon Laser-Scanning Microscopy Study Stroke, May 1, 2008; 39(5): 1556 - 1562. [Abstract] [Full Text] [PDF]

				A. Nimmagadda, H.-P. Park, R. Prado, and M. D. Ginsberg Albumin Therapy Improves Local Vascular Dynamics in a Rat Model of Primary Microvascular Thrombosis: A Two-Photon Laser-Scanning Microscopy Study Stroke, January 1, 2008; 39(1): 198 - 204. [Abstract] [Full Text] [PDF]

				L. B. Goldstein Acute Ischemic Stroke Treatment in 2007 Circulation, September 25, 2007; 116(13): 1504 - 1514. [Full Text] [PDF]

				M. D. Ginsberg Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era Stroke, June 1, 2007; 38(6): 1967 - 1972. [Abstract] [Full Text] [PDF]

				A. Muscari and M. Zoli Albumin-Induced Hematocrit-Lowering and B-type Natriuretic Peptide Increase Stroke, March 1, 2007; 38(3): 858 - 858. [Full Text] [PDF]

				M. D. Ginsberg, M. D. Hill, and Y. Y. Palesch Response to Letter by Muscari and Zoli Stroke, March 1, 2007; 38(3): 859 - 859. [Full Text] [PDF]

				J. Parkkinen, P. Ojala, J. Niiranen, and J. Jolkkonen Molecular Mechanisms Underlying Neuroprotective Effects of Albumin After Ischemic Stroke Stroke, February 1, 2007; 38(2): 255 - 255. [Full Text] [PDF]

				G. M.T. Hare At what point does hemodilution harm the brain?/A quel niveau d'hemodilution endommage- t-on le cerveau ? Can J Anesth, December 1, 2006; 53(12): 1171 - 1174. [Full Text] [PDF]

				Y. Y. Palesch, M. D. Hill, K. J. Ryckborst, D. Tamariz, and M. D. Ginsberg The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--II: Neurologic Outcome and Efficacy Analysis Stroke, August 1, 2006; 37(8): 2107 - 2114. [Abstract] [Full Text] [PDF]